Inventia Life Science develops the RASTRUM™ 3D cell culture platform, combining printers and bioinks to create human-like 3D tissue models for cancer research, drug discovery and other biomedical applications. The company plans to market RASTRUM worldwide and has launched US operations, appointing Dwayne Dexter as Director of US Sales to expand its pharmaceutical and academic customer base in the US and Canada. Inventia currently counts three leading US pharmaceutical companies as customers and says the platform enables testing in a 3D cellular environment that is more predictive than traditional models. Through its recently closed $25M Series B led by Blackbird Ventures, Inventia intends to scale commercial adoption and grow headcount from 36 to 150 employees by the end of 2024. The Series B brings total funding to date to $32M, including significant re-investment from Skip Capital. The company was founded in 2013 and is headquartered in Sydney, Australia.

Total raised

$25M

Funding rounds

1

Latest round

Series B

Latest activity

Dec 2021